Efficacy and Safety of Isatuximab Subcutaneous (SC) Plus Carfilzomib and Dexamethasone (Isa-Kd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results of the Phase 2 Study IZALCO

Article2025

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vânia Hungria, Meletios A Dimopoulos, Sosana Delimpasi, Jiří Minařík, Luděk Pour, Graça Esteves, Kazutaka Sunami, Junichiro Yuda, Ivan Spicka, Roman Hájek, Christine Soufflet, Disa Yu, Vera Hermina Kalika Koch, Florence Suzan, Hang Quach

Article2018

Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).

Thomas G. Martin, Meletios A Dimopoulos, Kwee Yong, Joseph Mıkhael, Marie‐Laure Risse, Gaëlle Asset, Philippe Moreau

Article2025

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

Gurdeep Parmar, Vânia Hungria, Meletios A Dimopoulos, Sosana Delimpasi, Fernanda Salles Seguro, Roman Hájek, Luděk Pour, Ivan Špıčka, Jiří Minařík, Marcelo Capra, Junichiro Yuda, Kazutaka Sunami, Herlander Marques, Graça Esteves, Christine Soufflet, Disa Yu, Erin Comerford, Florence Suzan, Paúl Cordero, Rick Zhang, Hang Quach

Article2019

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Joseph Mıkhael, Marie‐Laure Risse, Gaëlle Asset, Thomas Martin

Article2025

Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)

María-Victoria Mateos, Ivan Špıčka, Andrew Spencer, Albert Oriol, Fredrik Schjesvold, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Claudio Cerchione, Philippe Moreau, Erin Comerford, Florence Suzan, Maya Stefanova-Urena, Paúl Cordero, Rick Zhang, Sikander Ailawadhi

Discussion(0)

Related publications

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).

Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)